Following Monday’s clinical defeat by Eli Lilly, Novo Nordisk cut the 2027 list prices for its three GLP-1 medicines by as ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

A NOVEL non-peptide glucagon-like peptide-1 receptor agonist (GLP-1) pill is more effective for weight loss than oral ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial ...

NVO shares plunge 21% after Lilly's Zepbound and oral orforglipron beat its key GLP-1 drugs in head-to-head obesity and ...

Add Yahoo as a preferred source to see more of our stories on Google. Having an oral version of the medication, which had only been available as an injectable until now, is a “very big deal,” says ...

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that ...

The manufacturing of GLP-1s involves a complex process that includes peptide synthesis, amino acid coupling, cleavage, purification, and chemical modifications. The solid-phase peptide synthesis (SPPS ...

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also ...

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year ...

Walgreens is wading into the self-pay GLP-1 space, going head-to-head with telehealth subscription offerings. | Walgreens is wading into the self-pay GLP-1 space, going head-to-head with telehealth ...

If you miss a dose of GLP-1, you may be able to take it right away or wait until your next scheduled dose. It depends on the medication you take and how many doses you’ve missed. Glucagon-like peptide ...